NCT04485104 - Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 19, 2021

Primary Completion Date

January 28, 2025

Study Completion Date

January 28, 2025

Conditions

Seizure in Participants With Tuberous Sclerosis ComplexSeizure in Participants With Dravet SyndromeSeizure in Participants With Lennox-Gastaut Syndrome

Interventions

DRUG

GWP42003-P

Oral Solution

Trial Locations (11)

16147

Clinical Trial Site, Genova

28034

Clinical Trial Site, Madrid

45229

Clinical Trial Site, Cincinnati

50139

Clinical Trial Site, Florence

60611

Clinical Trial Site, Chicago

72202

Clinical Trial Site, Little Rock

77030

Clinical Trial Site, Houston

90095

Clinical Trial Site, Los Angeles

02114

Clinical Trial Site, Boston

00165

Clinical Trial Site, Rome

08950

Clinical Trial Site, Barcelona